等待開盤 10-18 09:30:00 美东时间
-0.370
-0.74%
Q32 Bio press release (NASDAQ:QTTB): Q2 GAAP EPS of -$1.42. Cash, cash equivalents, and short-term investments of $107.6 million as of June 30, 2024, More on Q32 Bio Russell 2000 rise: Top 5 best, wo...
08-08 20:50
Q32 Bio (QTTB) has issued an announcement. Q32 Bio Inc. has successfully comple...
07-09 19:28
WALTHAM, Mass., July 1, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune hom...
07-01 18:59
英飞朗: 隔夜涨幅15.8%,诺基亚计划收购Infinera,提升光网络市场竞争力
06-29 09:52
BBY: 4% | UBS Upgrades Best Buy Co to Buy, Raises Price Target to $106 ZYME: 13% | Zymeworks shares are trading higher after the FDA cleared the company's Investigational New Drug application for
06-17 20:40
In a report released today, Jay Olson from Oppenheimer maintained a Buy rating ...
05-13 19:55
Q32 Bio(QTTB.US):2024年Q1财报实现营收0美元,前值为294.7万美元,预期值为17万美元;每股收益为-6.33美元,前值为-19.84美元...
05-09 21:41
Cash, cash equivalents, and short-term investments were $135.3 million as of March 31, 2024, which are expected to provide financial runway through four Phase 2 clinical milestones and into mid-2026.
05-09 19:41
Gainers: Allarity Therapeutics (ALLR) +36%. Q32 Bio QTTB +15%. Entera Bio (ENTX) +16%. Mobile-health Network Solutions (MNDR) +13%. Theravance Biopharma (TBPH) +11%. Losers: Veru (VERU) -12%. Adial ...
04-12 22:00
Q32 Bio(QTTB.US)获奥本海默首次覆盖,给予优于大市评级, 目标价50.00美元。
04-11 17:51